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Research Article
Spastin recovery in hereditary spastic paraplegia by
preventing neddylation-dependent degradation
Francesca Sardina1 , Alessandra Pisciottani1, Manuela Ferrara1, Davide Valente1,5 , Marialuisa Casella2,
Marco Crescenzi2, Angelo Peschiaroli3, Carlo Casali4, Silvia Soddu5, Andrew J Grierson6, Cinzia Rinaldo1,5
Hereditary Spastic Paraplegia (HSP) is a neurodegenerative disease
most commonly caused by autosomal dominant mutations in the
SPG4 gene encoding the microtubule-severing protein spastin. We
hypothesise that SPG4-HSP is attributable to reduced spastin
function because of haploinsufficiency; thus, therapeutic ap-
proacheswhich elevate levels of thewild-type spastin allelemay be
an effective therapy. However, until now, how spastin levels are
regulated is largely unknown. Here, we show that the kinase HIPK2
regulates spastin protein levels in proliferating cells, in differen-
tiated neurons and in vivo. Our work reveals that HIPK2-mediated
phosphorylation of spastin at S268 inhibits spastin K48-poly-
ubiquitination at K554 and prevents its neddylation-dependent
proteasomal degradation. In a spastin RNAi neuronal cell model,
overexpression of HIPK2, or inhibition of neddylation, restores
spastin levels and rescuesneurite defects. Notably, wedemonstrate
that spastin levels can be restored pharmacologically by inhibiting
its neddylation-mediated degradation in neurons derived from a
spastin mouse model of HSP and in patient-derived cells, thus
revealing novel therapeutic targets for the treatment of SPG4-HSP.
DOI 10.26508/lsa.202000799 | Received 28 May 2020 | Revised 14 October
2020 | Accepted 14 October 2020 | Published online 26 October 2020
Introduction
Spastin is an AAA ATPase microtubule (MT)-severing enzyme that
regulates cytoskeleton rearrangement associated with membrane
remodeling. It is a critical regulator in cytokinesis and nuclear
envelope resealing during cell division and it is also involved in
intracellular traffic (1, 2, 3). In neurons, spastin has key roles in
axonal transport and regeneration (4, 5, 6). This enzyme functions
as hexamers that drive the remodeling and severing of MT by
tugging the C-terminal tail of tubulin through the central pore of
the hexamer (7, 8, 9). Thus far, four spastin isoforms have been
identified, M1 (68 kD), a shorter isoform lacking the first 86 aa (M87,
60 kD), and splice variants of both of these, excluding exon 4
(M1∆4, 64 kD, and M87∆4, 55 kD). M1 and M87 are synthesized
simultaneously but at largely different levels because the first
AUG is surrounded by a weak Kozak sequence resulting in a
preferred translation from the second AUG (10, 11). Splice variants
are the least abundant isoforms, for which no specific functions
have been reported thus far.
It has been suggested that precise regulation of spastin is critical
to prevent its dysfunction (5, 6). SPG4 mutations are the most
common cause of autosomal dominant Hereditary Spastic Para-
plegia (HSP), a neurodegenerative disease characterized by pro-
gressive spasticity of the lower limbs (12, 13, 14, 15, 16). Because most
of the SPG4 pathogenic mutations are nonsense, frameshift or large
insertion/deletion mutations that are generally associated with
nonsense mediated degradation of mRNA, haploinsufficiency is
considered one of the main molecular mechanisms of the disease
(17, 18, 19). In a subset of patients carrying missense mutations
dominant-negative effect, threshold-effect-model and gain-of-
function appear to be relevant (16, 20, 21). Axonal swellings,
characterized by aberrant accumulation of neurofilaments and
mitochondria, and abnormal organelle distribution/trafficking are
the hallmarks of axonal defects in mouse and human SPG4-HSP
models (22, 23, 24, 25). Loss-of-function mouse SPG4-HSP models
show motor behavior deficits and axon trafficking impairment;
heterozygous mice show very mild phenotypes compared with the
homozygous ones, further supporting a dosage effect (22, 23).
Studies on neurons generated from SPG4-HSP patient-derived
induced Pluripotent Stem cells, reported spastin reduction asso-
ciated with alterations in neurite morphology, swellings and
transport deficits (24, 25). Currently, there is no cure for HSP. Im-
portantly, in patients’ neurons a spastin gene dosage-dependent
rescue of the defects has been recently reported by lentiviral
spastin expression, providing proof of principle that spastin ele-
vating approaches could be a therapeutic strategy (25). However, at
present little is known about the molecular mechanisms regulating
endogenous spastin protein levels.
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Recently, we identified spastin as novel target of the multi-
functional kinase HIPK2 (26), that is highly expressed in the nervous
system (27, 28). We demonstrated that HIPK2-mediated phos-
phorylation of spastin at serine 268 is required for its midbody
localisation and successful abscission. Here, we show that spastin
levels are regulated by HIPK2-mediated phosphorylation and
neddylation-dependent degradation, providing evidence that it is
possible to restore spastin levels and reduce axonal swelling pa-
thology by targeting these pathways in SPG4-HSP models.
Results
Spastin protein levels are regulated by HIPK2 at
post-transcriptional level
During previous studies we noticed a reduction of spastin protein
levels upon HIPK2 depletion in HeLa cells, suggesting that HIPK2 might
control spastin protein levels (26). To verify this hypothesis, we per-
formed HIPK2-depletion by RNAi, CRE-Lox or CRISPR/Cas9 recombi-
nation in cells of different origin and analysed spastin protein levels
with different anti-spastin Abs (Figs 1A and B and S1A). Compared with
control cells, reduction of spastin levels was observed in all the HIPK2-
deficient cells obtained (Figs 1A and B and S1A) and was rescued after
HIPK2 re-expression in HeLa HIPK2-Cas9 cells (Fig 1C). Notably, spastin
reduction was observed upon HIPK2 depletion in murine neuron-like
NSC34 differentiated cells (Figs 1D and S1B and C), in human SH-SY-5Y
neuron-like differentiated cells (data not shown) and in primary
cortical neurons explanted from CRE-inducible Hipk2 KO mice upon
infection with an adenovirus expressing the recombinase CRE (Figs 1E
and S1D), showing that spastin levels are regulated by HIPK2 in
postmitotic differentiated primary neurons.
Consistent with these observations, analysis of spastin expression in
cerebral cortex (CC) and striatum (STR) explanted from Hipk2KOF/KOF
mice, showing strongly reduced HIPK2 levels compared with wild-type
(WT) siblings (Fig S1E and F), revealed a significant reduction of the
protein levels of all detectable spastin isoforms, whereas spastin mRNA
levelswereunchanged (Fig 1F andG). This suggests thatHIPK2might also
control spastin protein levels in the central nervous system (CNS) in vivo.
As reciprocal approach, we showed that HIPK2 up-regulation,
obtained by either overexpression of the exogenous protein or heat
shock–mediated stabilization (29) of the endogenous one, was
associated with increased spastin expression (Figs 1H and S1G).
Altogether these findings demonstrate that spastin is regulated
by HIPK2 in proliferating cells, in differentiated neurons and in vivo.
To investigateHIPK2–mediated regulationof spastin, we analysedboth
spastin mRNA and protein levels in HIPK2-depleted (siHIPK2) and control
cells (siCtr). The decrease in spastin protein expression occurs without
significant change at the mRNA level upon HIPK2 depletion (Figs 1I and J
and S1H), indicating post-transcriptional regulation of protein levels.
Spastin is polyubiquitinated at K554R and degraded via
proteasome in HIPK2-defective cells
Next, we performed protein degradation tests and observed that
spastin protein levels could be rescued by treatment with the
proteasome inhibitor MG132 in HIPK2-depleted cells (Fig 2A), sug-
gesting that degradation of spastin is mediated by the ubiquitin
proteasome pathway (UPP). Thus, we investigated whether spastin
is polyubiquitinated in HIPK2-defective cells. By using an anti-Ub Ab
recognising mono- and poly-Ub conjugates, a pattern of slowly
migrating spastin-Ub conjugates was detectable after spastin IP in
HIPK2-depleted cells post MG132 treatment (Figs 2B and C and S2A).
To further validate spastin polyubiquitination, we performed
ubiquitination assays in HeLa HIPK2-Cas9 and in Ctr-Cas9 cells,
using HA-tagged Ub-WT (Ub-HA) or lysine-free Ub mutant (koUb-
HA), which allows only monoubiquitination. IP with normal mouse
IgG immunoglobulins was used as negative control (Fig S2B). No
ubiquitination signals were observed in cells expressing koUb-HA
mutant, whereas a smear of slowly migrating spastin-Ub-HA con-
jugates accumulated in Ub-WT-expressing cells after MG132
treatment in HIPK2-Cas9 cells (Fig 2D), indicating spastin poly-
ubiquitination. Similar results were obtained also in parental Ctr-
Cas9 cells (Fig 2D). Next, we performed a ubiquitination assay using
a K48-only Ub mutants (K48-Ub-HA), which allows only K48-linked
polyubiquitinated chains, the canonical proteasomal degradation
signal. Spastin K48-polyubiquitination was detectable after MG132
treatment in HeLa HIPK2-Cas9 and in Ctr-Cas9 cells (Fig S2C and D).
Altogether, these findings indicate the involvement of the UPP
pathway in the regulation of spastin, even if we cannot rule out the
involvement of other non-proteolytic processes.
Among all the lysines of spastin that are possible sites for Ub
conjugation, K554 was reported as a putative site in a large-scale
mass spectrometry (MS) screen (https://www.phosphosite.org;
(30)). Thus, we focused our attention on this lysine residue which is
evolutionary conserved (Fig 2E) and located in the ATPase domain
common to all spastin isoforms. We generated a spastin K554
mutant (spastin-K554R), and tested it in ubiquitination assays. Flag-
myc tagged spastin-K554R and spastin-WT were expressed in
combination with Ub-HA in HIPK2-Cas9 cells. As shown in Figs 2F
and S2E, spastin-WT displayed a smear of slowly migrating bands
comparable to that of the endogenous protein, whereas spastin-
K554R showed a very strong reduction of this pattern, indicating
that K554 is a key spastin polyubiquitination site (Fig 2F). Accord-
ingly, when transfected at comparable efficiency, spastin-WT levels
were reduced in HIPK2-Cas9 cells compared with HIPK2 proficient
cells, whereas spastin-K554R was expressed at similar levels in both
cell types, suggesting that spastin-K554R is more resistant to
protein degradation than spastin-WT (Fig 2G). These results show
that K554 polyubiquitination is required for spastin degradation in
HIPK2-defective cells.
HIPK2 regulates spastin protein levels through its kinase activity
We have demonstrated that HIPK2 binds and phosphorylates
spastin at S286 (26), thus we analysed whether HIPK2 regulates
spastin protein levels through its kinase activity. Compared with
HIPK2-WT–overexpressing cells, no increase in spastin protein
levels was observed upon transfection of the kinase-defective
HIPK2-K228A mutant (Fig 3A), consistent with a role for HIPK2
kinase activity in coordinating the ubiquitination of spastin. By
using vectors encoding non-phosphorylatable or phosphomimetic
spastin mutants, S268A and S268D, respectively, we noticed that
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Figure 1. HIPK2 regulates spastin at posttrascriptional levels.
(A) Indicated cells were transfected with amix of three human HIPK2-specific (siHIPK2) or negative control (siCtr) stealth siRNAs and analysed by Western blot (WB) 96 h
posttransfection. Unless otherwise indicated, here and in the following figures representative WB of three independent experiments was shown and the intensity of the
spastin bands quantified, normalized with GAPDH, and reported in a.u. relative to control, as mean ± SD of three independent experiments. Molecular weight markers are
reported in kilodalton. Here, spG311/1 Ab was used for spastin detection and statistical differences are relative to corresponding siCtr, unpaired t test. (B) HeLa cells
were transfected with vectors expressing control LacZ sh-RNA (sh-Ctr) or a mix of two HIPK2-specific shRNAs (sh-HIPK2) and analysed by WB 72 h posttransfection (left
panels). HeLa HIPK2-Cas9 cells and their parental control cells (Ctr-Cas9) were analysed by WB 24 h after plating (right panels). Statistical differences are relative to
corresponding control, unpaired t test. (C) HeLa HIPK2-Cas9 cells were transfected with low dose of HIPK2-HA–expressing vector to avoid apotosis induction and
analysed by WB 24 h posttransfection with anti-HIPK2 and anti-spastin Abs. Statistical difference is relative to empty vector transfected cells used as control, unpaired t
test. (D)NSC34 cells were transfected with amix of threemouse HIPK2-specific (siHIPK2) or negative control (siCtr) stealth siRNAs and incubated in differentiation medium;
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spastin-S268A was reproducibly and consistently expressed at
lower levels than spastin-WT or spastin-S268D when transiently
transfected at comparable efficiency (Fig 3B). Accordingly, spastin-
S268A displayed a shorter half-life than spastin-WT in the presence
of cycloheximide (Fig 3C), indicating that HIPK2-mediated S268
phosphorylation contributes to spastin stability.
HIPK2-dependent S268 phosphorylation prevents spastin
polyubiquitination and degradation
Next, we asked whether S268 phosphorylation is required to
prevent spastin polyubiquitination. Thus, we compared on the
same blot the polyubiquitination levels among WT, non-
phosphorylatable, and phosphomimetic spastin forms in the
presence or absence of HIPK2. For clarity, we have presented
these data in two separate panels (Fig 4A and B). The non-
phosphorylatable spastin-S268A mutant is the most poly-
ubiquitinated in HIPK2 proficient Ctr-Cas9 cells (Fig 4A),
whereas the phosphomimetic spastin-S268D mutant is the
least polyubiquitinated in the HIPK2-Cas9 cells (Fig 4B), in-
dicating that HIPK2-mediated S268-phosphorylation prevents
spastin polyubiquitination. Accordingly, when transfected at
comparable efficiency in HIPK2 proficient and in HIPK2-KO
cells, the phosphomimetic spastin-S268D mutant, but not
the WT form, is resistant to degradation (Figs 4C and S3).
Overall, these findings indicate that HIPK2-mediated S268
phosphorylation protects spastin from polyubiquitination at
K554 and degradation.
We next addressed the mechanism by which S268 phos-
phorylation regulates ubiquitination. We hypothesised that S268
phosphorylation can protect spastin from polyubiquitination by
impairing the recruitment of proteins belonging to the ubiq-
uitination pathway or by promoting interactions with factors that
mask the domain of spastin necessary for efficient ubiquitination/
degradation. To investigate this, we used MS to analyse the
interactome of exogenous spastin-S268A and spastin-S268D in
HeLa cells (Supplemental Data 1). Among the known interacting
proteins, we found atlastin (31), and spastin itself (7, 8, 32). In-
terestingly, we found Cullin-Associated NEDD8-Dissociated Pro-
tein 1 (CAND1) as a unique spastin-S268D interactor and this
preferential interaction was confirmed by co-IP experiments (Fig
4D). Next, we verified spastin/CAND1 endogenous interaction (Fig
4E). According to exogenous co-IP results, we observed that the
interaction is stronger in HIPK2 proficient cells than in HIPK2-Cas9
cells, further supporting a preferential interaction between CAND1
and phosphorylated spastin (Fig 4E). CAND1 is a known inhibitor of
Cullin-RING ubiquitin E3-Ligase (CRL) complexes (33), its inter-
action with spastin suggests involvement of the neddylation
pathway in spastin degradation via UPP.
Spastin levels and neurite defects can be restored by preventing
neddylation-dependent degradation in different SPG4-HSP
models
To investigate the biological relevance of HIPK2-mediated spastin
protein regulation, we analysed the effects of neddylation-mediated
UPP inhibition and HIPK2 overexpression on spastin protein levels
in pathological conditions due to spastin reduction. We hypoth-
esised that as HIPK2 expression, the neddylation inhibitors, such as
MLN4924/pevonedistat (33, 34), would stabilize spastin preventing
its degradation and subsequently rescue the pathological phe-
notypes associated to spastin reduction. To test this hypothesis,
first we verified whether MNL4924 treatment stabilizes spastin by
preventing its polyubiquitination (Fig S4A and B). Next, wemimicked
typical pathological SPG4-HSP phenotypes depleting spastin via
RNAi in NSC34 differentiated cells. As expected, spastin reduction
caused neurite swelling defects (5, 23; Fig S4C) and we observed and
quantify these defects (Fig 5B and D, see the light orange columns).
In this spastin RNAi neuronal cell model, we observed that HIPK2
overexpression (Fig 5A) or treatment with a low non-toxic dose of
MLN4924 (Fig 5C) led to an increase in spastin protein levels and a
rescue of neurite swelling (Fig 5A–D), confirming our hypotheses.
These results provide evidence that targeting the HIPK2/spastin
axis might be a strategy to develop spastin-elevating therapeutic
approaches.
Relevant from a clinical point of view, MLN4924 is a CNS-
penetrant drug that is currently in several phase 1–3 clinical tri-
als for different malignancies (https://clinicaltrials.gov/ct2/results?
term=pevonedistat). Thus, we evaluated whether MLN4924 treatment
is able to increase the levels of normal spastin allele in the context
of pathological heterozygous SPG4-HSP mutations. To address this
issue, we used two different SPG4-HSP models. First, cortical
neurons explanted from heterozygous ΔE7 SPG4 mice and second
patient’s derived human lymphoblastoid cells carrying heterozy-
gous c751insA mutation. Both models express approximately 50%
levels of spastin WT and undetectable levels of truncated proteins
(23 and data not shown). MLN4924 treatment increased spastin
protein levels in both models (Fig 5E and F). Importantly, the in-
crease in spastin levels produced by MNL4924 treatment restored
levels close to those of control cells (Fig 5E and F), demonstrating
that MLN4924 is able to restore para-physiological spastin levels in
SPG4-HSP haploinsufficient context.
5 d post siRNA transfection cells were analysed by WB. Statistical difference, unpaired t test. (E) Cortical neurons at 5 days in vitro (DIV5) derived from indicated mouse
infected with adenovirus expressing the recombinase CRE were analysed by WB 96 h postinfection. Statistical difference, unpaired t test. (F, G) Indicated neural tissues
were explanted from Hipk2+/+ and Hipk2KOF/KOF adult mice (5 mo) and spastin levels were analysed by WB and real time RT-PCR. (F) Representative WB showing the
reduction of spastin isoforms is reported; statistical differences are relative to corresponding control tissue, unpaired t test. (G) Relative fold-change of spastin mRNA
levels, using actin mRNA as normalizer, are represented as mean ± SD of three independent experiments in (G); ns, no statistically significance, unpaired t test. (H)
Representative WB of HeLa cells transfected with GFP (empty) or GFP-HIPK2–expressing vectors and lysed 24 h posttransfection. Statistical difference, unpaired t test. (I, J)
HeLa cells transfected as in Fig 1A were analysed by WB and real-time RT-PCR at the indicated time post transfection. In (I), representative WB, statistical differences are
relative to corresponding siCtr, unpaired t test; in (J), relative fold-change of spastin mRNA levels, using GAPDH mRNA as normalizer, as mean ± SD of three independent
experiments. ns, unpaired t test.
Source data are available for this figure.
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Figure 2. HIPK2 regulates spastin via proteasomal degradation through K554 polyubiquitination.
(A) Representative Western blot (WB) of HeLa cells transfected as in Fig 1A and lysed 96 h posttransfection and 8 h after treatment with 20 μMMG132 or its solvent DMSO.
MDM2 stabilization has shown as MG132 positive control. Statistical differences, ANOVA test. (B) HeLa cells were transfected as in Fig 1A and harvested 96 h
posttransfection and 8 h after treatment with 20 μM MG132 or DMSO. Total cell extract (TCE) was analysed by WB for the indicated proteins and immunoprecipitated with
anti-spastin Ab. IPs were analysed by WB with anti-Ub and anti-spastin Abs. The arrow indicates the position of the unmodified spastin and the asterisk indicates a
nonspecific band. The intensity of spastin-Ub ladder was normalized by the intensity of spastin band in IP and reported relative to siCtr DMSO–treated cells as mean ± SD
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Discussion
We have identified and characterized a pathway responsible for the
stability of the spastin protein, which is mutated in the most common
form of autosomal dominant HSP, and exploited this knowledge to
propose a novel approach for corrective elevation of spastin levels in
disease by preventing its neddylation-dependent degradation. In
particular, the present study shows that HIPK2-mediated phosphor-
ylation of spastin at S268 inhibits spastin K48-polyubiquitination at
K554 and prevents its neddylation-dependent proteasomal degra-
dation, correlating HIPK2-mediated phosphorylation and spastin
stability. Our findings support the hypothesis that spastin protein
levels are controlled by a balance between the S268 phosphorylation
and polyubiquitination/degradation processes (Fig 6).
The precise mechanism by which S268 phosphorylation protects
from polyubiquitination remains to be further characterized. The
preferential interaction of phosphorylated spastin with CAND1,
which functions as substrate receptor exchange factor for CRL1 and
4 complexes (34, 35, 36), supports a model in which the phos-
phorylation of spastin might alter the dynamic equilibrium with its
specific receptor. Therefore, we hypothesized that the enhanced
CAND1/spastin interaction might induce a decrease of the ex-
change possibility necessary for the active CRL complex formation.
Nevertheless, we cannot exclude that binders of the p-S268 spastin
might act sterically inducing conformational changes that hide
site/s for successful ubiquitination. Interestingly, katanin, a MT-
severing enzyme belonging to the same ATPase family as spastin, is
regulated via phosphorylation/polyubiquitination crosstalk in-
volving similar regions of the protein as we describe for spastin (37,
38, 39), opening the possibility of a more general mechanism for
spatio-temporal regulation of ATPases presenting the same do-
main architecture as spastin and katanin.
Furthermore, because both spastin and HIPK2 have been shown
to play roles in different biological processes, our data open the
possibility that HIPK2-mediated spastin regulation can function as
a fine-tuning regulator in multiple spastin-dependent processes,
such as nuclear envelope resealing, cytokinesis and trafficking (1, 3).
Recently, spastin severing activity was shown to elicit two different
outcomes: the extraction of tubulin subunit from the MT might be
counteract by spontaneous incorporation of soluble GTP-tubulin or
provoke the severing when extraction outpaces repair (7). We might
hypothesize cellular modulation of these two outcomes by locally
controlling spastin protein levels acting on the balance between its
phosphorylation and ubiquitination/degradation (Fig 6). Further
layers of complexity are conceivable considering that spastin levels
appear strictly regulated to avoid its accumulation, likely via the
action of specific phosphatase/s, deubiquitinase/s, and other
factors regulating spastin expression.
Curative therapies and approaches to manage HSP diseases are
completely lacking and therapy is only symptomatic. Based on
literature evidence (17) and our findings, we hypothesized that
elevating spastin by inhibiting its neddylation-dependent degra-
dation might be a novel possible therapeutic approach in SPG4-
HSP. The existence of a CNS-penetrant drug, such as MLN4924, that
(i) blocks NEDD8-activating enzyme, (ii) is currently in several
clinical trials, (iii) has been shown to increase the survival of Spinal
Muscolar Atrophy- and Amyothrophic Lateral Sclerosis-derived
motorneurons and ameliorate the in vivo phenotype of Spinal
Muscolar Atrophymousemodel (40), prompted us to directly assess
whether this drug increases the levels of functional spastin in
SPG4-HSP haploinsufficient contexts. Our findings indicate that
MNL4924 might be a novel spastin-elevating compound, without
adverse effects on cell viability.
There are several limitations in this study. We have to consider
that neddylation-dependent degradation controls a broad set of
proteins and preclinical studies in opportune animal models have
to be carried out to assess whether MNL4924 is effective in relieving
HSP pathological features. SPG4-HSP shows mild phenotype in
homozygote mouse models compared with the severity of the
symptoms in HSP patients. The mouse model that we used in this
study was an essential mammalian model to be tested for a rescue
of spastin levels in neurons. However, its “very weak” swelling
phenotype in heterozygous mutant neurons prevents us from
assessing the rescue of axon swelling phenotype. Therefore, studies
on animal models with a stronger phenotype at the heterozygous
status (such as, Drosophila melanogaster or Caenorhabditis ele-
gans) would be required to fully validate the therapeutic impact of
this compound.
Spastin-elevating approaches are not the best therapeutic
strategy for the less common missense variants of spastin, acting
with pathogenic mechanism other than haploinsufficiency (e.g.,
dominant-negative or gain-of-function mechanisms). However, it
will be interesting to assess the response to UPP of each of these
variants. We might speculate to extend this approach to those that
(n = 3). Statistical differences, ANOVA test. (C) NSC34 cells were transfected as in Fig 1B and harvested 5 d posttransfection and 8 h after treatment with 20 μMMG132. TCE
was analysed by WB for the indicated proteins and immunoprecipitated with anti-spastin Ab. IPs were analysed by WB with anti-Ub and anti-spastin Abs. The arrow
indicates the position of the unmodified spastin and the asterisk indicates a specific band. The intensity of spastin-Ub ladder was calculated and reported as in Fig 2B.
Statistical differences, ANOVA test. (D)HeLa Ctr-Cas9 and HIPK2-Cas9 cells were transfected with vectors expressing HA-tagged Ub-WT (Ub-HA) or its derivative KoUb-HA
(i.e., Ub with all lysines mutated in arginines) and treated 24 h posttransfection with 20 μMMG132 or DMSO for 8 h. TCEs were analysed as in Fig 2B. IPs were analysed by WB
with anti-HA and anti-spastin Abs. The arrow indicates the position of the unmodified spastin and the asterisk indicates a nonspecific band. The intensity of spastin-Ub-
HA ladder was normalized by the intensity of spastin band in IP and reported relative to the correspondent DMSO-treated cells as mean ± SD (n = 3). Statistical
differences, ANOVA test. (E) Spastin amino acid sequence encompassing the K554 is reported for indicated organisms. Fly = Drosophila melanogaster; worm =
Caenorhabditis elegans. (F) HIPK2-Cas9 HeLa cells were transfected with vectors expressing flag-myc–tagged spastin-WT or spastin-K554R in combination with the vector
expressing HA-tagged Ub-WT and treated 24 h posttransfection with 20 μMMG132 for 8 h. TCE were analysed byWB and immunoprecipitated with anti-Flag Ab (mouse Ab
by Origene Technologies). IPs were analysed by WB with anti-HA and anti-Flag Ab (rabbit Ab by Sigma-Aldrich). The arrows indicate the position of the unmodified spastin
isoforms. The intensity of spastin-Ub-HA ladder was normalized by the intensity of spastin bands in IP and reported as mean ± SD (n = 4). Statistical difference, unpaired t
test. (G) HIPK2-Cas9 and Ctr-Cas9 HeLa cells were transfected with vectors expressing spastin-WT or spastin-K554R in combination with peGFP vector at 10:1 molar ratio
and analysed by WB 24 h posttransfection. GFP expression was used as internal control for transfection efficiency. Representative WB is shown. The intensity of spastin-
Flag bands was normalized by the intensity of GFP and reported relative to correspondent Ctr-Cas9 control cells. Statistical differences, ANOVA test.
Source data are available for this figure.
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show a partial loss of activity triggering degradation. Spastin WT
stabilization could alleviate also the pathogenicity of mutants
resulting in loss of ATPase activity, such as the I344K variant (41).
Preclinical studies with MT-targeting drugs have shown preliminary
promising effects for HSP treatment (42, 43), the effects of very low
dose of these drugs combined with spastin inhibition of degra-
dation might be also evaluated.
Finally, the possibility to pharmacologically modulate spastin
levels opens the way to potential clinical implications also in
promoting axon regeneration after nerve injury (6, 44) and in
neurodegenerative diseases associated to spastin dysfunctions,
such as Alzheimer’s disease (45, 46).
In conclusion, we have identified and characterized a novel
pathway regulating spastin protein levels via HIPK2-mediated
phosphorylation that prevents spastin neddylation-dependent
degradation. Intriguingly, we show that inhibition of neddylation by
using the CNS penetrant drug MLN4924 is able to restore spastin
levels and rescue neurite defects. Even though many factors have
to be considered before initiating preclinical studies for MLN4924
repurposing in SPG4-HSP, our novel findings provide proof of
Figure 3. Kinase activity of HIPK2 regulates spastin protein levels.
(A) Representative Western blot (WB) of HeLa (right panels) and NSC34 cells (left panels) transfected with vectors expressing HA-tagged HIPK2-WT, its derivative -K228A
mutant or HA-alone (empty). Statistical differences, Anova test. (B) Representative WB of HeLa cells transfected with vectors expressing flag-myc spastin-WT or indicated
spastin mutants in combination with peGFP vector at 10:1 molar ratio and lysed at indicated time post transfection. GFP expression was used as internal control for
transfection efficiency. The intensity of spastin-Flag bands was normalized by the intensity of GFP and reported relative to spastin-WT for each time point. Statistical
differences, ANOVA test. (C) HeLa cells were transfected with vectors expressing flag-myc–tagged spastin-S268A or spastin-WT, treated with 25 μg/ml cycloeximide 36 h
posttransfection and analysed by WB at indicated times after treatment. Note that to minimize differences in spastin levels at the time 0, cells were transfected with
different doses of the expressing vectors, that is, 1 μg of spastin-S268A–expressing vector and 0.5 μg of spastin-WT–expressing vectors. Representative WB is shown. The
levels of spastin-Flag bands relative to those of GAPDH were measured at each time point and reported as mean ± SEM of four different independent experiments in the
right panel. Statistical differences were calculated and reported for each time point, unpaired t test.
Source data are available for this figure.
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Figure 4. Phosphorylation in S268 prevents spastin polyubiquitination and degradation.
(A, B) HeLa Ctr-Cas9 (A) and HIPK2-Cas9 (B) cells were transfected with vectors expressing indicated flag-myc–tagged spastin-WT or its derivative mutants in
combination with the vector expressing HA-tagged Ub-WT and treated 24 h posttransfection with 20 μMMG132 for 8 h. Total cell extracts (TCEs) were analysed by Western
blot (WB) and IP as in Fig 2F. Samples were processed in parallel and analysed on the same blot to make comparison between HIPK2 proficient and null cells. The arrows
indicate the position of unmodified spastin isoforms. The intensity of spastin-Ub-HA ladder was normalized by the intensity of spastin-Flag bands in IP and reported as
mean ± SD (n = 3). Statistical differences, ANOVA test. (C) HeLa Crt-Cas9 and HIPK2-Cas9 cells were transfected with vectors expressing indicated flag-myc–tagged spastin
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principle that elevating spastin by inhibiting its UPP-mediated
degradation has therapeutic potential for SPG4-HSP patients.
Materials and Methods
Cells, culture conditions, and treatments
HeLa (a gift of N Corbi), A549 (a gift of R Falcioni), U2OS (a gift of F
Moretti), and retinal pigment epithelial (a gift of G Guarguaglini)
were cultured at 37°C and 5% CO2 in DMEM GlutaMAX supplemented
with 10% heat-inactivated FBS (Life Technologies); mouse moto-
neuronal NSC34 (a gift of M Cozzolino) was cultured in DMEM-F12 1:1,
supplemented with 10% FBS. Patient-derived lymphoblastoid cells,
carrying the pathogenetic heterozygous c751insA SPG4 mutation,
were cultured in RPMI supplemented with 10% FBS. To obtain
homogeneous neuronal cell cultures, SNSC34 were differentiated
by incubation in serum-free medium supplemented daily with 10
μM retinoic acid (Sigma-Aldrich) and 10 ng/ml GDNF (Peprotech).
HeLa HIPK2 null (HIPK2-Cas9) and their parental control (Ctr-Cas9)
cells (47) were kindly provided by ML Schmitz. Cells were routinely
tested for mycoplasma contamination.
Mice carrying Hipk2 KO first conditional-ready alleles (Hipk2KOF/KOF;
https://www.mousephenotype.org/data/genes/MGI:1314872) were gen-
erated by the International KO mouse consortium by inserting into the
HIPK2 loci a lacZ cassette, which traps and truncates the nascent
transcript, leading to 80% of Hipk2 mRNA reduction. Primary cortical
neurons from CRE-inducible Hipk2 KO alleles (Hipk2cKO/cKO) were ob-
tained by inbreeding Hipk2KOF/KOF mice with mice carrying FLP recom-
binase (https://www.jax.org/strain/005703), and neurons from SPG4 ΔE7/+
and +/+mice (23) were prepared and cultured as previously described
in reference 23. Adenovirus expressing CRE is a kind gift of D Pajalunga.
The following inhibitors were used: MG132 and cycloeximide
(Sigma-Aldrich) and MLN4924 (Cayman Chemical). For the evalua-
tion of cell viability, trypan blue dye exclusion test was used to
determine the number of viable cells.
RNAi and real-time RT-PCR
HIPK2 RNAi was obtained in human cells by using specific stealth
siRNAs (a mix of three different validated siRNAs by Life Tech-
nologies, as in reference 48) or by transfecting HIPK2-specific sh-
RNA–expressing vectors (a mix of pRetroSuper-1376 and -789, (49)).
HIPK2 RNAi in murine cells and spastin RNAi in human cells were
obtained by using a mix of specific validated stealth siRNAs by Life
Technologies; for spastin, RNAi-specific siRNAs were selected
among which targeting sequences common to all spastin isoforms
as in reference 26. siRNAs were transfected using Lipofectamine
RNAi MAX (Life Technologies). RNA extraction and real-time RT-PCR
were performed as in reference 48, and relative fold-change were
determined by the 2−ΔΔCt method using GAPDH or actin mRNA as
normalizer. All reactions were performed in triplicate, in three
independent experiments. Primers for HIPK2 and spastin amplifi-
cation are as references 48 and 50, respectively. The spastin primers
amplify a region common to all spastin isoforms. The sequences of
the siRNAs used are the following:
murine-specific siHIPK2 #1: CCACCAACUUGACCAUGACCUUUAA; #2: GA-
GCCAAGUUCCAACUGGGACAUGA; #3: GCCCAUGUCAAAUCUUGUUUCCAAA.
human-specific siHIPK2 #1: CCCGAGUCAGUAUCCAGCCCAAUUU; #2:
CCACCAACCUGACCAUGACCUUUAA; #3: CAGGGUUUGCCUGCUGAAUAUUUAU.
human/murine-specific siSpastin #1: CCAGUGAGAUGAGAAAUAUUCGAUU,
#2 CGGACGUCUAUAACGAGAGUACUAA.
Expression vectors
The following plasmids were used: peGFP-c2 (Clontech); peGFP-human-
HIPK2, flag empty and flag-HIPK2, pET-HA, pET-human-HIPK2-HA, and
pET-human-HIPK2-K228A-HA (Kind gifts of ML Schmitz); pSUPER-LacZ
and pSUPER-HIPK2-1376 and pSUPER-HIPK2-789 (49), pEF-HA-Ub-WT,
and pEF-HA-KoUb (kind gift of A Pollice); pRK5-HA-Ub-K48, pRK5-HA-
Ub-WT, and pcDNA3-Myc3-CAND1 (Addgene); Flag-myc empty vector
(pCMV6-Entry) and flag-myc–tagged spastin expressing vector (OriGene
Technologies). The latter vector expresseshigher levels of theM1 isoform
than the corresponding M87, in agreement with data showing that M1 is
themost abundant formwhen both isoforms have equally good Kozak’s
sequences (51). Spastin-S268A and Spastin-S268D mutants were de-
scribed in reference 26, and spastin-K554Rwas obtainedby site-directed
mutagenesis in the spastin-flag-myc–tagged vector using the Quik-
Change Lightning Kit (Stratagene) and analysed by sequencing. Vectors
were transfected by using Lipofectamine LTX and Plus reagent (Life
Technologies).
Western blot (WB) and immunopecipitation (IP)
Total cell extracts were prepared in RIPA buffer (50 mM Tris–HCl, pH
8, 150mMNaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP40, and 1
mM EDTA) supplemented with protease and phosphatase inhibitors
(Roche). For ubiquitination assays, we first performed WB analysis
with anti-spastin or anti-Flag antibodies (Abs) on 1/15 of our IP
reactions to determine the efficiency of IP in each sample. After this
WT or its derivative S268D in combination with peGFP vector as in Fig 2G and analysed by WB 24 h post transfection. GFP expression was used as internal control for
transfection efficiency. Representative WB is shown. The intensity of spastin-Flag bands was normalized by the intensity of GFP and reported relative to Ctr-Cas9 control
cells. Statistical differences, Anova test. (D) Representative Co-IP showing that spastin-S268D preferentially binds CAND1. HeLa cells were co-transfected with the plasmid
expressing MYC-CAND1 in combination with empty vector or vectors expressing spastin-S268A or spastin-S268D. Cells were collected 24 h posttransfection. TCE were
analysed by WB or immunoprecipitated with anti-Flag or anti-CAND1 Abs and analysed as indicated. The asterisk indicates an aspecific band. TCE and IP samples were
loaded on the same gel and processed on the same filter. Blots were vertically cropped to show appropriate expositions. Full blots are shown in the source data F4 file. (E)
Co-IP showing that spastin interaction with CAND1 is stronger in HeLa Ctr-Cas9 cells compared with HIPK2-Cas9 cells. TCE from Ctr-Cas9 and HIPK2-Cas9 cells were
analysed by WB or immunoprecipitated with anti-spastin Ab and analysed with indicated Abs. IgG immunoglobulins were used as IP negative control. Band intensities of
co-immunoprecipitated CAND1 were normalized by band intensities of spastin immunoprecipitated and their relative values are reported as mean ± SD (n = 3). Statistical
difference, unpaired t test.
Source data are available for this figure.
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Figure 5. Restoration of spastin protein levels and neurite swelling in SPG4-(HSP) Hereditary Spastic Paraplegia models.
(A, B) NSC34 cells were transfected with 40 nM spastin-specific (siSpastin) or negative control stealth siRNAs and incubated in differentiation medium. 48 h post siRNA
transfection cells were transfected with empty or HIPK2 expressing vectors and analysed by Western blot (WB) and by IF using anti-acetylated-tubulin Ab (green) and
mitotracker (red) 5 d after siRNA transfection and differentiation. (A) Representative WB is shown in (A); the intensity of the spastin bands were quantified, normalized and
reported relative to empty vector in siCtr and in siSpastin cells as mean ± SD of three independent experiments. Statistical differences, unpaired t test. (B) The
percentage of swelling is reported in (B) as mean ± SD of three different experiments in which >100 cells were analysed. Statistical differences, ANOVA test. Representative
image of neurite swelling is shown. Scale bar, 10 μM. (A, C, D) NSC34 cells were transfected as in (A) and incubated in differentiation medium. 72 h post siRNA transfection
cells were treated with MLN4924 0.1 μm or its solvent DMSO and analysed 16 h after treatment. (C) Representative WB is shown in (C). Cullin deneddylation is shown as
MNL4924 positive control. The intensity of the spastin bands were quantified, normalized and reported relative to solvent-treated cells in siCtr and in siSpastin as mean ±
SD of three independent experiments. Statistical differences, unpaired t test. (D) The percentage of swelling is reported in (D) as mean ± SD of three different experiments
in which >100 cells were analysed. Statistical differences, Anova test. Representative image of neurite swelling is shown. Scale bar, 10 μM. No dead cells were observed
after treatment. (E) Representative WB showing the increase of endogenous spastin protein levels 72 h after 0.1 μM MLN4924 treatment in indicated primary cortical
neurons derived from SPG4 WT (+/+) and heterozygous (+/Δ7) E5 mice. The intensity of the spastin bands were quantified, normalized and reported relative to solvent-
treated cells in neurons derived from SPG4 WT (+/+) and heterozygous (+/Δ7) as mean ± SD of two independent experiments. (F) Representative WB showing the
increase of endogenous spastin protein levels 16 h after 0.1 μMMLN4924 treatment in SPG4-HSP lymphoblastoid cells. The intensity of the spastin bands were quantified,
normalized and reported relative to solvent-treatment in healthy donors lymphoblastoid cells and in patient’s derived SPG4-HSP lymphoblastoid cells. Statistical
differences, unpaired t test.
Source data are available for this figure.
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quantification, we loaded similar levels of immunoprecipitated spastin
and performedWBwith anti-ubiquitin (Ub) or anti-HA Abs, depending on
the experimental conditions. Proteins were resolved by SDS–PAGE using
Bolt Novex Bis-Tris Gels 4–12% gradient or 8% (Life Technologies).
Immunoreactivity was determined using ECL-Prime (Amersham), and
image acquisition and densitometric analysis were performedwith Image
Lab software (Bio-Rad). The following antibodies were used: anti-HIPK2
(ratmonoclonal Ab C5C6 kindly provided byML Schmitz); anti-GAPDH #sc-
32233 (1:1,000), anti-α-tubulin #sc-5286 (1:1,000), anti-vinculin #73614 (1:
1,000), anti-spastin mouse monoclonal Abs (1:100; sp3G11/1 #sc-53443 or
sp6c6 #sc-81624), and anti-spastin goat polyclonal Ab #sc-49528 (1:1,000)
by Santa Cruz Biotechnology (anti-spastin monoclonal Abs were indif-
ferently used because they produce comparable results, whereas anti-
spastin polyclonal Ab was used by WB to detect immunoprecipitated
spastin inmurine cells); antiβ3-tubulin #5568 (1:1,000) and anti-MYC #2276
(1:500) mouse monoclonal Abs (Cell Signaling Technology); anti-CAND1
#NBP1-49918 (1:1,000) rabbit polyclonal Ab (Novus Biological); anti-Ub
#BML-PW8810-0100 (1:1,000, clone FK2; Enzo Life Sciences); anti-HA
#11583816001 (1:1,000) mouse monoclonal Ab by Roche; anti-GFP (1:800,
mouse monoclonal Ab by Roche or 1:200 #sc-390394 rabbit polyclonal Ab
by Santa Cruz Biotechnology); anti-Flag (1:1,000; rabbit polyclonal Ab,
#F7425, by Sigma-Aldrich or mouse monoclonal Ab, #TA50011; OriGene
Technologies); anti-Nedd8 #ab81264 (1:500) rabbit monoclonal Ab by
Abcam, anti-Cul1 #612040 (1:500)mousemonoclonal Ab by BD bioscience;
and anti–HRP-conjugated goat anti-mouse #7076, anti-rat #7077, and anti-
rabbit #7074 (Cell Signaling Technology).
Normal mouse IgG #sc-2025 by Santa Cruz Biotechnology was
used as isotype control immunoglobulins in IP experiments.
MS analysis
24 h after transfection with flag-myc–tagged spastin-S268A or
-S268D expressing vectors in HeLa cells extracts were obtained by
lysing the cells in RIPA buffer supplemented with protease and
phosphatase inhibitors (Roche). IP was performed by incubation of
2 mg of total cell extract with anti-flag Ab (mouse Ab by Origene
Technologies) covalent coupled to Dynabeads M-280 Tosylacti-
vated according to the according to manufacturer’s protocol (Life
Technologies). Beads coupled to an unrelated Ab (i.e., anti-E1A
mouse monoclonal Ab; BD Bioscience) were used as negative
control. Each sample was separated on a 1D-gel NuPAGE 4–12%
(Invitrogen), run in MOPS buffer, and stained with the Colloidal Blue
Staining kit (Invitrogen). Gel lanes were entirely subdivided into
slices and subjected to reduction, alkylation, and trypsin digestion
(52). The resulting peptide mixtures were desalted in a trap column
(Acclaim PepMap 100 C18, LC Packings; DIONEX), and then separated
in a 10-cm reverse-phase column (Silica Tips FS 360-75-8; New
Objective) and slurry-packed in house with 5 μm, 200. Å pore size
C18 resin (Michrom BioResources). Separation was performed with
an Ultimate 3000 nanoflow HPLC (DIONEX) connected with an LTQ-
XL mass spectrometer (ThermoElectron), equipped with a nano-
electrospray ion source (ESI).
The list of identified interactors by one experimental replicate
has been deposited to the ProteomeXchange Consortium (see the
Data Availability section).
Immunofluorescence (IF) and swelling analysis
Cells were seeded onto poly-L-lysine–coated coverslips, fixed in 2%
formaldehyde, permeabilized in 0.25% Triton X-100 in PBS for 10 min,
and then blocked in 5% bovine serum albumin in PBS before the
primary Ab was applied. The following Abs were used: anti β3-tubulin
#5568 (1:500 mouse monoclonal Abs by Cell Signaling Technology)
and anti-acetyl-α-tubulin #T7451 (1:500 mouse monoclonal Ab by
Sigma-Aldrich). Secondary mouse FITC Ab #A32723 (Alexa-fluor; Life
Technologies) was used. DNA was marked with DAPI (Sigma-Aldrich)
Figure 6. Schematic model depicting the regulation
of spastin protein levels.
Because S268-phosphorylation (indicated with a blue
P) prevents polyubiquitination of spastin, its protein
levels are the consequence of a balance between
phosphorylation and degradation events depending
on HIPK2 kinase activity and the function of a still
unknown CRL complex. Based on this model, low
HIPK2 activity reduces the spastin phosphorylated
forms leading to an increase of spastin
polyubiquitination with a consequent decrease of
spastin protein levels due to proteasomal degradation.
In contrast, high HIPK2 activity protects spastin from
polyubiquitination, increasing its protein levels.
When polyubiquitination is prevented using the
neddylation inhibitor, MLN4924, spastin protein levels
increase independently of its phosphorylation
status.
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and mitochondria with mitotracker Red #M22425 (Life Technolo-
gies). Cells were examined under inverted microscope (Eclipse Ti;
Nikon) using a Clara camera (ANDOR Technology). Images for each
sample were taken in parallel using identical microscope by Nis-
Elements H.C. 5.11 using the JOBS module for automated acquisi-
tions. Swelling quantitative analysis was performed as in reference
23. Briefly, swelling was defined along the neurite revealed with
acetyl-tubulin and inside mitochondrial staining as larger than 2
μm in diameter; random fields were analysed after staining with
mitotracker and the number of swelling scored per at least 100 DAPI
stained nuclei.
Genotyping PCR
Genomic DNA was extracted using DirectPCR lysis reagent (Viagen),
and PCR analysis was carried out using GoTaq DNA polymerase
(Promega) following the supplier’s conditions. Alleles were iden-
tified using the following primers: for Hipk2 wild type (Forward 59-
CGATCGAGTAAGGGTCGGTG-39, Reverse 59-GATGTGTGCTTGAGGCTTGC-
39); for Hipk2 KOF (Forward 59-TTATGGTCTGAGCTCGCCATCAGT-39,
Reverse 59-TGTTTCTCCATGGACAGTGGGTT-39); for Hipk2 cKO and
KO alleles (distinguishable by different amplicon size; Forward
59-AAGGCGCATAACGATACCACG-39, Reverse 59-CTGTTTCTCCATGGA-
CAGTGGGTT-39).
Statistical analysis
Data analyses were performed using the GraphPad Prism software.
Each experiment has been repeated from three to four times and
the results obtained presented as mean ± SD, unless otherwise
indicated. The unpaired t test or ANOVA test were applied to de-
termine the significance of quantitative experiments. Statistical
significance was set at P < 0.05 and was reported by asterisks
according to the following scheme ****P < 0.00001, ***P < 0.0001, **P <
0.001, and *P < 0.05.
Ethics statement
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of the National Institutes of Health, according to the current Na-
tional Legislation (Art. 31 D.lgs 26/2014, 4 March, 2014) and were
approved by National Institutes of Health (1056/2015). The ethics
committee of Asl Roma 2, Rome, Italy, approved this study on
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